Historical Information for RDRC Program
The Radioactive Drug Research Committee (RDRC) program began when the Food and Drug Administration published a Federal Register notice on July 25, 1975 classifying all radioactive drugs as either new drugs requiring an Investigational New Drug Application (IND) for investigational use (21 CFR 312) or as generally recognized as safe and effective when administered under the conditions specified in the RDRC regulations (21 CFR 361.1).
- November 16, 2004 Public Meeting Information
- Society of Nuclear Medicine Annual Meeting Presentations (June 14-18, 2008)
- The Radioactive Drug Research Committee (RDRC): 2008 Update, Orhan H. Suleiman MS, PhD, FAAPM
- The Radioactive Drug Research Committee (RDRC) Reporting Requirements, Susan Lange, ARRT, MPH